Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation

10 Sep 2013

Four companies have brought noninvasive prenatal testing to the market within the past two years. Its dramatic, rapid uptake has triggered a backlash among many geneticists, who fear the consequences of a poorly understood – and overhyped – technology.

Since the commercial introduction of Sequenom Inc.’s MaterniT21 test in October 2011, noninvasive prenatal testing (NIPT) has become the hottest – and most controversial – area of clinical genomics.

The drive toward NIPT was rooted in the bold dream of replacing invasive diagnostic testing for genetic disorders, which entails karyotyping (chromosome counting) using chorionic villus sampling (CVS) or

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

16 May 2025

• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

15 May 2025

• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

13 May 2025

• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

12 May 2025

• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.